Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Clinical Trial of Berubicin for the Treatment of Glioblastoma (GBM)

Trial Profile

A Phase IIa Clinical Trial of Berubicin for the Treatment of Glioblastoma (GBM)

Planning
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs Berubicin (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors CNS Pharmaceuticals
  • Most Recent Events

    • 25 Apr 2018 As per CNS Pharmaceuticals website, the company expects to commence this phase 2a trial in 2018.
    • 25 Apr 2018 New trial record
    • 18 Apr 2018 According to a CNS Pharmaceuticals media release, this trial is expected to be funded in part by an equity crowdfunding campaign.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top